lysocin E: isolated from Lysobacter; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Lysocin E is a lipopeptide with antibiotic activity against methicillin-resistant Staphylococcus aureus. It binds to its menaquinone (commonly known as vitamin K)
| Excerpt | Reference | Relevance |
|---|---|---|
| "Lysocin E is a lipopeptide with antibiotic activity against methicillin-resistant Staphylococcus aureus. " | ( Serum apolipoprotein A-I potentiates the therapeutic efficacy of lysocin E against Staphylococcus aureus. Hamamoto, H; Inoue, M; Ishii, K; Itoh, H; Miyashita, A; Panthee, S; Paudel, A; Sekimizu, K; Su, J; Tokumoto, K; Yasukawa, J, 2021) | 2.3 |
| "Lysocin E is an antibiotic that showed antibacterial activity against Staphylococcus aureus by binding to its menaquinone (commonly known as vitamin K" | ( Lysocin E Targeting Menaquinone in the Membrane of Mycobacterium tuberculosis Is a Promising Lead Compound for Antituberculosis Drugs. Geberetsadik, G; Hakamata, M; Hamamoto, H; Hayatsu, M; Ilinov, A; Inaizumi, A; Kaboso, SA; Matsumoto, S; Mizutani, Y; Nishiyama, A; Ozeki, Y; Panthee, S; Sekimizu, K; Tamaru, A; Tateishi, Y; Yamaguchi, T, 2022) | 2.89 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.37) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 5 (31.25%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (68.75%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||